Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 13/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 13/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 13/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 13/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 13/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 13/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 13/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.70 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.70 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.70 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440205 | 0.86 | GRIN2D (0.76) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| 2,3-Dihydroxy-6,7-Dichloroquinoxaline SCHEMBL30561497 | 0.83 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| 2,3-Dihydroxy-6,7-Dichloroquinoxaline SCHEMBL463608 | 0.83 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL121942 | 0.83 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22198960 | 0.79 | GRIN2D (0.66) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19068666 | 0.77 | ALDH1A1 (0.70) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7469933 | 0.74 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21949134 | 0.74 | GRIA1 (0.78) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL27474539 | 0.74 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9389319 | 0.73 | GRIN2D (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670774-A1 | QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005033088-A1 | QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-14 | — | — | WO | disclosed |
| US-20050070527-A1 | For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
| CN-1103770-C | Quinoxalinediones | PFIZER RES AND DEV CO N V S A (IE) | 2003-03-26 | — | — | CN | disclosed |
| EP-1218370-A2 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Aventis Pharma S.A. (FR) | 2002-07-03 | — | — | EP | disclosed |
| EP-0783495-B1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LTD (GB) | 2002-02-27 | — | — | EP | disclosed |
| EP-0885212-B1 | QUINOXALINEDIONES | PFIZER RES AND BR DEV COMPANY (IE) | 2001-11-14 | — | — | EP | disclosed |
| WO-2001025227-A2 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA S.A. (FR) | 2001-04-12 | — | — | WO | disclosed |
| US-5863917-A | ANXIOLYTIC AGENT, ANTICONVULSANTS, ANALGESICS AND NEUROPROTECTIVES. | PFIZER, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0885212-A1 | QUINOXALINEDIONES | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-12-23 | — | — | EP | disclosed |
| US-5852016-A | Quinoxaline derivatives useful in therapy | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1997032873-A1 | QUINOXALINEDIONES | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997031902-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-09-04 | — | — | WO | disclosed |
| EP-0792874-A1 | Quinoxaline derivatives useful in therapy | Pfizer Limited (GB) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996009295-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070527-A1 | For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions | HRH4, HRH3, LTB4R | GRIN2D 1163/4885GRIN3B 525/4885GRIN1 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.